UY29756A1 - Derivados de 5-piridazinil-1-azabiciclo(3.2.1) octano, su preparación y su aplicación en terapéutica. - Google Patents

Derivados de 5-piridazinil-1-azabiciclo(3.2.1) octano, su preparación y su aplicación en terapéutica.

Info

Publication number
UY29756A1
UY29756A1 UY29756A UY29756A UY29756A1 UY 29756 A1 UY29756 A1 UY 29756A1 UY 29756 A UY29756 A UY 29756A UY 29756 A UY29756 A UY 29756A UY 29756 A1 UY29756 A1 UY 29756A1
Authority
UY
Uruguay
Prior art keywords
piridazinil
azabiciclo
octano
therapeutics
derivatives
Prior art date
Application number
UY29756A
Other languages
English (en)
Inventor
Galli Frederic
Leclerc Odile
Lochead Alistair
Vache Julien
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36297201&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29756(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY29756A1 publication Critical patent/UY29756A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de azabiciclo(3.2.1)octano que se utilizan para el tratamiento de alteraciones cognitivas.
UY29756A 2005-08-18 2006-08-18 Derivados de 5-piridazinil-1-azabiciclo(3.2.1) octano, su preparación y su aplicación en terapéutica. UY29756A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0508594A FR2889847B1 (fr) 2005-08-18 2005-08-18 Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.

Publications (1)

Publication Number Publication Date
UY29756A1 true UY29756A1 (es) 2007-03-30

Family

ID=36297201

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29756A UY29756A1 (es) 2005-08-18 2006-08-18 Derivados de 5-piridazinil-1-azabiciclo(3.2.1) octano, su preparación y su aplicación en terapéutica.

Country Status (40)

Country Link
US (3) US7476674B2 (es)
EP (1) EP1922320B1 (es)
JP (1) JP5249758B2 (es)
KR (1) KR101260546B1 (es)
CN (2) CN102558177A (es)
AR (1) AR056461A1 (es)
AT (1) ATE486073T1 (es)
AU (1) AU2006281340B2 (es)
BR (1) BRPI0614796A2 (es)
CA (1) CA2618110C (es)
CR (1) CR9693A (es)
CY (1) CY1111101T1 (es)
DE (1) DE602006017854D1 (es)
DK (1) DK1922320T3 (es)
DO (1) DOP2006000191A (es)
EA (1) EA013601B1 (es)
EC (1) ECSP088182A (es)
ES (1) ES2354833T3 (es)
FR (1) FR2889847B1 (es)
HK (1) HK1125628A1 (es)
HN (1) HN2008000276A (es)
HR (1) HRP20110043T1 (es)
IL (1) IL189014A0 (es)
JO (1) JO2680B1 (es)
MA (1) MA29913B1 (es)
MX (1) MX2008002276A (es)
MY (1) MY145923A (es)
NO (1) NO20081289L (es)
NZ (1) NZ565537A (es)
PE (1) PE20070234A1 (es)
PL (1) PL1922320T3 (es)
PT (1) PT1922320E (es)
RS (1) RS51653B (es)
SI (1) SI1922320T1 (es)
TN (1) TNSN08026A1 (es)
TW (1) TWI322808B (es)
UA (1) UA92360C2 (es)
UY (1) UY29756A1 (es)
WO (1) WO2007020343A1 (es)
ZA (1) ZA200800966B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249307B2 (en) 2011-08-16 2016-02-02 Pierce Biotechnology, Inc. Benzocyanine compounds
JP7476100B2 (ja) 2018-07-19 2024-04-30 住友ファーマ株式会社 ピリダジノン誘導体
WO2021141041A1 (ja) 2020-01-07 2021-07-15 大日本住友製薬株式会社 タウオパチーの治療剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
FR2786770B1 (fr) * 1998-12-04 2001-01-19 Synthelabo Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
ES2223209B1 (es) 2001-12-11 2005-10-01 Esteve Quimica, S.A. Nuevas formas cristalinas del meloxicam y procedimientos para su preparacion e interconversion.
ES2269467T3 (es) 2000-10-13 2007-04-01 Neurosearch A/S Tratamiento de transtornos afectivos por la accion combinada de un agonista del receptor nicotinico y una sustancia monoaminergenica.
FR2834511B1 (fr) * 2002-01-07 2004-02-13 Sanofi Synthelabo Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique
US6644511B2 (en) 2002-01-11 2003-11-11 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Container for dispensing a dual phase fluid product

Also Published As

Publication number Publication date
MY145923A (en) 2012-05-15
US20080176855A1 (en) 2008-07-24
EP1922320B1 (fr) 2010-10-27
SI1922320T1 (sl) 2011-02-28
FR2889847A1 (fr) 2007-02-23
CN101291933B (zh) 2012-03-14
NO20081289L (no) 2008-03-17
US7476674B2 (en) 2009-01-13
AU2006281340A1 (en) 2007-02-22
CA2618110A1 (fr) 2007-02-22
ZA200800966B (en) 2009-04-29
BRPI0614796A2 (pt) 2011-04-12
CY1111101T1 (el) 2015-06-11
NZ565537A (en) 2011-04-29
PT1922320E (pt) 2011-01-19
CN102558177A (zh) 2012-07-11
TNSN08026A1 (en) 2009-07-14
US20120046298A1 (en) 2012-02-23
KR20080034468A (ko) 2008-04-21
TW200738715A (en) 2007-10-16
ATE486073T1 (de) 2010-11-15
KR101260546B1 (ko) 2013-05-06
WO2007020343A1 (fr) 2007-02-22
MA29913B1 (fr) 2008-11-03
RS51653B (en) 2011-10-31
HK1125628A1 (es) 2009-08-14
AR056461A1 (es) 2007-10-10
IL189014A0 (en) 2008-08-07
JO2680B1 (en) 2013-03-03
CR9693A (es) 2008-03-06
ES2354833T3 (es) 2011-03-18
TWI322808B (en) 2010-04-01
US8076340B2 (en) 2011-12-13
US8557819B2 (en) 2013-10-15
EP1922320A1 (fr) 2008-05-21
MX2008002276A (es) 2008-03-27
HN2008000276A (es) 2011-03-30
DK1922320T3 (da) 2011-02-21
US20090088440A1 (en) 2009-04-02
FR2889847B1 (fr) 2007-10-05
UA92360C2 (en) 2010-10-25
HRP20110043T1 (hr) 2011-02-28
JP2009504714A (ja) 2009-02-05
AU2006281340B2 (en) 2012-04-12
CA2618110C (fr) 2014-02-11
CN101291933A (zh) 2008-10-22
DOP2006000191A (es) 2011-11-15
EA200800615A1 (ru) 2008-06-30
EA013601B1 (ru) 2010-06-30
JP5249758B2 (ja) 2013-07-31
DE602006017854D1 (de) 2010-12-09
PE20070234A1 (es) 2007-03-26
PL1922320T3 (pl) 2011-04-29
ECSP088182A (es) 2008-03-26

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
CL2007003202A1 (es) Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
CL2008001721A1 (es) Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
WO2006124748A3 (en) Multicyclic compounds and methods of their use
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
EA201071291A2 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
CL2007002635A1 (es) Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
TW200736227A (en) New compounds III
TW200724140A (en) Hydantoin compounds
CL2009000281A1 (es) Compuestos derivados de 5,6-dihidro-pirrolo-[2,1-a]-isoquinolinas y pirrolo-[2,1-a]-isoquinolinas; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamaiento de trastornos de la fertilidad.
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119